Targovax’s ONCOS-102 receives FDA fast track designation for malignant pleural mesothelioma treatment
In a significant development for cancer treatment, Targovax, a Norwegian biotech firm specializing in immune-oncology, has announced that its lead candidate, ONCOS-102, has been granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of malignant pleural mesothelioma, a rare and aggressive cancer. FDA’s Recognition Enhances Clinical Development The FDA’s […]